COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
Jaguar Health, Inc. (NASDAQ:JAGX) has announced the publication of a study evaluating the effects of crofelemer in providing symptomatic relief of diarrhea associated with the irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor neratinib (Nerlynx®) in female dogs. The study, conducted by Napo Pharmaceuticals in collaboration with Puma Biotechnology, highlights the growing need for treatment of cancer therapy-related diarrhea (CTD), a common and debilitating side effect of patients undergoing cancer therapy. The findings of this study, along with two other important studies, provide scientific rationale for the use of crofelemer in humans for the prevention and treatment of CTD, addressing the unmet medical need in the age of targeted cancer therapies. -
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ:JAGX) granted 7,500 restricted stock units (RSUs) to a new employee, with vesting over three years. The RSUs were approved by the Compensation Committee of Jaguar's Board and are subject to the employee's continued service. Jaguar Health is a pharmaceutical company focused on developing prescription medicines derived from plants for gastrointestinal distress. -
COMMUNIQUÉ DE PRESSE
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
Napo Pharmaceuticals, a Jaguar Health family company, has received a new U.S. patent for methods to treat congenital diarrheal disorders with crofelemer, their novel plant-based prescription drug. This patent enhances their intellectual property protection for crofelemer and supports their focus on rare disease indications such as microvillus inclusion disease and short bowel syndrome. Jaguar is conducting investigator-initiated studies for these rare disease indications in multiple regions with results expected in 2024. -
-
-
COMMUNIQUÉ DE PRESSE
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Napo Pharmaceuticals and Advocates for Collaborative Education (ACE) have released the abstract for a quality of life survey for individuals with a cancer diagnosis, shedding light on the challenges faced. The survey findings will be presented at the December 2023 SABCS, focusing on the impacts of cancer diagnosis and treatment on quality of life, including physical and emotional well-being, treatment side effects, and the consequences of managing those side effects -
COMMUNIQUÉ DE PRESSE
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) has announced the renewal of conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets) by the U.S. FDA for the treatment of chemotherapy-induced diarrhea (CID) in dogs. The renewal extends the validity until December 21, 2024, as the company plans a clinical field study to support full approval -
COMMUNIQUÉ DE PRESSE
Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
Jaguar Health, Inc. to present on Dec 5, 2023, at the MedInvest Oncology Investor Conference, discussing pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy -
